HOST IMMUNE SIGNATURES AS THERAPY RESPONSE BIOMARKERS IN METASTATIC RENAL CELL CARCINOMA...NEW GRANT, SIGNED 8/29/2019, EFFECTIVE 9/15/2019, DISTRIBUTED 9/3/2019, FAADC 9/3/2019
$706,000FY2019Department of the ArmyDOD
Dana-Farber Cancer Institute, Inc.